Le Marec N, Ase A R, Botez-Marquard T, Marchand L, Reader T A, Lalonde R
Centre de Recherche en Sciences Neurologiques, Faculté de Médecine, Université de Montréal, Montreal, Quebec, Canada.
Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):333-42. doi: 10.1016/s0091-3057(01)00536-6.
The Lurcher mutant mouse can be considered an adequate model of autosomal dominant spinocerebellar atrophy because of the severe degeneration of its cerebellar cortex and inferior olive. The purpose of this study was to determine whether the motor coordination deficits of Lurcher mutants could be improved after chronic administration of the serotonin (5-hydroxytryptamine; 5-HT) precursor, L-tryptophan, or of the 5-HT(1A) agonist, buspirone. During these treatments, the mice were submitted to behavioral evaluations using the coat hanger and the rotorod tests, as well as an inclined screen and a vertical grid test. At the end of treatments, 5-HT and 5-hydroxindole-3-acetic acid (5-HIAA) were measured in six brain regions. On the coat hanger test, administration of L-tryptophan accelerated movements along the horizontal bar by 44%, while buspirone increased the time spent on the apparatus by 11%. Neither drug had an effect on climbing ability or on the time spent on a rotating beam. Administration of L-tryptophan increased 5-HIAA levels in frontal cortex, neostriatum, thalamus, brainstem, cerebellum and spinal cord, but elevated 5-HT only in neostriatum, brainstem and cerebellum. In contrast, buspirone led to 5-HT increases in cerebellum and augmented 5-HIAA in the spinal cord. The modest test-specific improvements are consistent with some of the clinical data concerning 5-HT pharmacotherapy in patients suffering from cerebellar atrophy.
由于Lurcher突变小鼠的小脑皮质和下橄榄核严重退化,它可被视为常染色体显性遗传性脊髓小脑萎缩的一个合适模型。本研究的目的是确定长期给予血清素(5-羟色胺;5-HT)前体L-色氨酸或5-HT(1A)激动剂丁螺环酮后,Lurcher突变小鼠的运动协调缺陷是否能够得到改善。在这些治疗过程中,使用衣架试验和转棒试验以及倾斜屏幕试验和垂直网格试验对小鼠进行行为评估。治疗结束时,测量六个脑区中的5-HT和5-羟吲哚-3-乙酸(5-HIAA)。在衣架试验中,给予L-色氨酸使沿水平杆的运动加速了44%,而丁螺环酮使在该装置上花费的时间增加了11%。两种药物对攀爬能力或在旋转杆上花费的时间均无影响。给予L-色氨酸使额叶皮质、新纹状体、丘脑、脑干、小脑和脊髓中的5-HIAA水平升高,但仅使新纹状体、脑干和小脑中的5-HT升高。相比之下,丁螺环酮使小脑中的5-HT增加,并使脊髓中的5-HIAA增加。这些适度的、针对特定试验的改善与一些关于小脑萎缩患者5-HT药物治疗的临床数据一致。